Robert F Webber

US Patent:

20050281826, Dec 22, 2005

Filed:

May 13, 2005

Appl. No.:

11/129452

Inventors:

Robert Webber - Las Vegas NV, US
Douglas Webber - Los Angeles CA, US
Thelma Dixon - Berkeley CA, US

International Classification:

A61K039/395

US Classification:

424146100

Abstract:

A therapeutic agent which removes or neutralizes iNOS in the blood of a mammalian subject. The agent may be in the form of an anti-iNOS monoclonal antibody or an iNOS binding entity.

US Patent:

20070042003, Feb 22, 2007

Filed:

Aug 19, 2005

Appl. No.:

11/208143

Inventors:

Robert Webber - Las Vegas NV, US
Douglas Webber - Los Angeles CA, US

International Classification:

A61K 39/02
A61K 31/739

US Classification:

424234100, 514054000

Abstract:

A method of effecting a model of sepsis, severe sepsis, or septic shock in a mammalian subject which utilizes the step of introducing particulate or vesicle associated iNOS into the body of the mammalian subject. Prior to or during such introduction, an innate immune system activator may be introduced into the body of the mammalian subject. Other substances may also be introduced into the mammalian subject prior to or during the introduction of the particulate or vesicle associated iNOS in order to observe the physiological consequences on the mammalian subject.

US Patent:

20070105780, May 10, 2007

Filed:

Nov 7, 2005

Appl. No.:

11/268946

Inventors:

Robert Webber - Las Vegas NV, US
Douglas Webber - Los Angeles CA, US

International Classification:

A61K 38/10

US Classification:

514015000

Abstract:

Treatment of SIRS, sepsis, severe sepsis and septic shock in a mammalian subject in which iNOS is present by decreasing the proteolytic cleavage of the iNOS protein using a protease inhibitor is described.

US Patent:

20070110738, May 17, 2007

Filed:

Nov 16, 2005

Appl. No.:

11/280049

Inventors:

Robert J. Webber - Las Vegas NV, US
Douglas S. Webber - Los Angeles CA, US

International Classification:

A61K 38/44

US Classification:

424094400

Abstract:

A treatment for SIRS, sepsis, severe sepsis and septic shock in a mammalian subject by utilizing a method and therapeutic agent for inhibiting the binding of particulate iNOS to cells. The agent takes the form of a cellular receptor antagonist.

US Patent:

20070269442, Nov 22, 2007

Filed:

May 19, 2006

Appl. No.:

11/437367

Inventors:

Robert J. Webber - Las Vegas NV, US
Douglas S. Webber - Las Vegas NV, US
Thelma H. Dixon - Las Vegas NV, US

International Classification:

A61K 39/395
C07K 16/40

US Classification:

4241461, 53038826

Abstract:

A chimeric therapeutic agent recognizing iNOS utilizing a human/mouse chimeric anti-hiNOS monoclonal antibody having mouse complimentarity-determining regions forming a binding site for iNOS.

US Patent:

20130004968, Jan 3, 2013

Filed:

Sep 20, 2011

Appl. No.:

13/200233

Inventors:

Robert Webber - Las Vegas NV, US

International Classification:

G01N 21/76
G01N 33/577
C12Q 1/26

US Classification:

435 79, 435 25, 435 71

Abstract:

A panel of blood biomarkers for assessing a sepsis condition utilizing an iNOS indicator in combination with one or more indicators of patient predisposition to becoming septic, the existence of organ damage, or the worsening or recovering from a sepsis episode.